Human Genome seeks FDA nod to market lupus drug
Says files Biologics License Application with FDA
Thursday, June 10, 2010
Human Genome Sciences Inc said it has sought for U.S. regulatory approval to market its experimental lupus drug Benlysta that the biopharmaceutical company is co-developing with partner GlaxoSmithKline Plc.
On the go?
Text INFO to 50555 and opt-in to receive breaking news about lupus on your mobile phone.
Message and Data Rates May Apply. Text STOP to 50555 to STOP. Text HELP to 50555 for HELP. Full Terms